Evotec : partner Exscientia reports topline data from EXS-21546 phase 1A study
June 14, 2022 at 08:13 am EDT
Share
CLINICAL DATA BUILDS UPON BODY OF EVIDENCE SUGGESTING EXS-21546 IS A HIGHLY POTENT AND SELECTIVE A2AR INHIBITOR WITH LOW CNS EXPOSURE
EXSCIENTIA ANTICIPATES INITIATING PHASE 1B/2 IN PATIENTS WITH HIGH ADENOSINE SIGNATURE CANCERS IN SECOND HALF OF 2022
ONGOING TRANSLATIONAL WORK TO ESTABLISH PREDICTIVE BIOMARKER TO ENABLE TARGETING OF PATIENTS MOST LIKELY TO BENEFIT FROM EXS-21546
Oxford, UK, 14 June 2022:
Evotec's partner Exscientia plc (NASDAQ: EXAI) today announced data from its Phase 1 healthy volunteer study of EXS-21546, its highly selective A2a receptor antagonist co-invented and developed through a collaboration between Exscientia and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO). Topline data from this healthy volunteer study confirmed Exscientia's target product profile design, including potency, high receptor selectivity and expected low brain exposure with no CNS adverse events reported, supporting advancement of EXS-21546 to a Phase 1b/2 study in patients with solid tumours exhibiting high
adenosine signatures.
Please follow this link to the full press release from Exscientia.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Evotec SE published this content on 14 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 June 2022 12:12:02 UTC.
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâs health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
EVOTEC SE 
